Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy, safety, tolerability and persistence of use of Lumigan ®
0.01% in patients diagnosed with primary open-angle glaucoma or ocular hypertension who are
treated per routine clinical practice.